CELZ Chief Scientific Advisor has been there done
Post# of 350
Thomas Ichim, Ph.D, Chief Scientific Advisor, has more than 20 years of broad biotechnology experience including filing and prosecuting patents (over 100 patents filed and issued), publishing in peer reviewed journals (110 publications) obtaining regulatory approvals, conducting clinical trials, and successfully providing return to investors by taking companies public or selling of companies. Dr. Ichim was cofounder of bioRASI, a fully integrated CRO which made the INC 500 list for fastest growing companies in the USA. He subsequently joined Medistem Inc, a stem cell company which was purchased by the NYSE traded company Intrexon. Dr. Ichim was co-founder of Batu Biologics, a cancer vaccine, Regen BioPharma, and Creative Medical Technology Holdings, both of which he successfully took public. Dr. Ichim is peer-reviewed for multiple scientific journals and sits on the Editorial Board of the Journal of Translational Medicine. Dr. Ichim is author/coauthor of multiple book chapters and 3 textbooks.
Creative Medical Technology Holdings Inc (CELZ) Stock Research Links
Lecture, University of Lille (7 December 1854)